FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC By Ogkologos - April 25, 2025 833 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAfore study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC ESMO Welcomes European Parliament (EP) report on Psychosocial Risks (PSR) at Work as a Key Step towards Protecting the Cancer Workforce and Ensuring High-Quality... MOST POPULAR Giving Birth Before Age 20 Cuts Breast Risk By 50%, And... December 12, 2019 FDA Approves Nivolumab for Adjuvant Treatment of Urothelial Carcinoma August 24, 2021 Deputy Spends His Days Off Teaching Life Skills To Young Boys... December 26, 2021 FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection October 2, 2024 Load more HOT NEWS Adagrasib Shows Promising Activity as Monotherapy, Even Greater in Combination with... Treatment with a Hypomethylating Agent Can Activate or Up-regulate Oncogenes New ESMO Framework to Resolve Uncertainties About the De-intensification of Cancer... T-DM1 Approval Expanded to Include Some Women with Early-Stage HER2-Positive Breast...
